Search by Abstract Number Results

Abstract Number: 0530 • ACR Convergence 2024
Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein², Marike van der Leeden², Franktien Turkstra², Jos Twisk³, Maarten Boers³, Henriët van Middendorp⁴, Peter Weijs⁵ and Dirkjan van Schaardenburg⁶, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁴Leiden University, Leiden, Netherlands, ⁵Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle intervention, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 0530 • ACR Convergence 2023
Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial
Jeffrey Curtis¹, Rebecca Grainger², Dan Webster³, Jie Shen⁴, Ana Biljan⁵, Anna Shmagel⁴, Peter Wung⁴ and Philip J. Mease⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Wellington, New Zealand, ³AbbVie, Inc., Libertyville, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Buffalo Grove, IL, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Physical activity is associated with reduced pain, improved mobility and physical function in people with ankylosing spondylitis (AS) and plays a crucial role in…
Abstract Number: 0530 • ACR Convergence 2022
Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)
Juergen Rech¹, Arnd Kleyer², Mikkel Østergaard³, Melanie Hagen², Larissa Valor Mendez², Koray Tascilar², Gerhard Kroenke², Verena Schönau², David Simon², stefan Kleinert⁴, Xenofon Baraliakos⁵, Juergen Braun⁶, Axel Hueber⁷, Martin Fleck⁸, Andrea Rubbert-Roth⁹, Frank Behrens¹⁰, Martin Feuchtenberger¹¹, M. Zaenker¹², Reinhard Voll¹³, Cornelia Glaser¹⁴, Mária Filková¹⁵, Eugen Feist¹⁶, Gerd Burmester¹⁷, Kirsten Karberg¹⁸, Johannes Strunk¹⁹, Juan Canete²⁰, Ladislav Šenolt¹⁵, Esperanza Naredo²¹ and Georg Schett²², ¹University Clinic Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ⁵Ruhr University Bochum, Department of Rheumatology, Bochum, Germany; Rheumazentrum Ruhrgebiet, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Klinikum Nuernberg Nord, Abteilung fuer Rheumatologie, Nuernberg, Germany, ⁸Asklepios Klinikum Bad Abbach, Klinik und Poliklinik für Rheumatologie/ Klin. Immunologie, Bad Abbach, Germany, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ¹⁰Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, ¹¹MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, ¹²Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, ¹³Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg im Breisgau, Germany, ¹⁴Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ¹⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁶Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ¹⁷Charité University Medicine Berlin, Berlin, Germany, ¹⁸Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, ¹⁹Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Koeln, Germany, ²⁰Unidad de Artritis Hospital Clinic, Barcelona, Spain, ²¹Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ²²Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA),…
Abstract Number: 0530 • ACR Convergence 2021
Dysregulation of IGFI/IGF1R Pathway and IGF1R+3179A/G Polymorphism in Pathogenesis of Sjögren’s Syndrome
Charalampos Skarlis¹, Adrianos Nezos², Nikolaos Marketos¹, Asimina Papanikolaou³, Athanasios Tzioufas⁴, Michael Koutsilieris¹, Haralampos Moutsopoulos⁵ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²National & Kapodistrian University of Athens, Athens, Greece, ³Department of Haemopathology, "Evangelismos" Hospital, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁵Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: Sjӧgren’s syndrome (SS) is an autoimmune exocrinopathy characterized by chronic salivary and lacrimal gland dysfunction. Alterations of Insulin-like growth factor (IGF) pathway has been…
Abstract Number: 0530 • ACR Convergence 2020
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
Jacqueline Madison¹, Kelsey Gockman¹ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].